Matches in Wikidata for { <http://www.wikidata.org/entity/Q65368182> ?p ?o ?g. }
Showing items 1 to 41 of
41
with 100 items per page.
- Q65368182 description "clinical trial" @default.
- Q65368182 description "ensayu clínicu" @default.
- Q65368182 description "klinisch onderzoek" @default.
- Q65368182 description "клінічне випробування" @default.
- Q65368182 name "Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases" @default.
- Q65368182 name "Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases" @default.
- Q65368182 type Item @default.
- Q65368182 label "Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases" @default.
- Q65368182 label "Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases" @default.
- Q65368182 prefLabel "Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases" @default.
- Q65368182 prefLabel "Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases" @default.
- Q65368182 P1132 Q65368182-D63EF554-4FDD-4CF6-8B36-5FE078C2E96A @default.
- Q65368182 P1476 Q65368182-4718D970-DC1D-4443-A5AD-6BEE48517D3B @default.
- Q65368182 P17 Q65368182-C1C519C8-566B-4FA1-A68B-ADDD23CC7A16 @default.
- Q65368182 P1813 Q65368182-C1E12DDC-F7F8-4265-BD42-8AEE1FA66834 @default.
- Q65368182 P2899 Q65368182-8CBA9449-45BE-47C7-9EAF-8058FAE08F45 @default.
- Q65368182 P3098 Q65368182-84E8BB8B-9FED-4F38-8088-110866467C8A @default.
- Q65368182 P31 Q65368182-112F7FEA-1350-4359-8ED3-DB7B395930F3 @default.
- Q65368182 P4844 Q65368182-2323317E-01E2-4A72-B001-227D537ED2E0 @default.
- Q65368182 P4844 Q65368182-240D8535-8AB7-4E6F-A19E-AF63D1A428D9 @default.
- Q65368182 P4844 Q65368182-DE2470FE-1F50-4560-BA5F-68E148EF42A7 @default.
- Q65368182 P4844 Q65368182-E7A3BD50-D26C-4CA6-B554-6D55ADD5C719 @default.
- Q65368182 P580 Q65368182-9F3C0F7C-F7E0-4FE5-AF06-EF61151178CD @default.
- Q65368182 P582 Q65368182-1B3E7458-6CC0-4E4D-AEC7-FC2D1802FD0B @default.
- Q65368182 P6099 Q65368182-DC09F5AF-9E0F-44CA-AF30-11193B589C92 @default.
- Q65368182 P8363 Q65368182-0F34D80D-D17D-4BC9-ACEC-F975B152A5A1 @default.
- Q65368182 P1132 "+256" @default.
- Q65368182 P1476 "Open, Randomized, Multicenter Phase II Trial With Cetuximab /5-FU/FA/Irinotecan or Cetuximab/5-FU/FA /Irinotecan/Oxaliplatin in K-ras/B-raf Wild Type Patients or With Irinotecan/Oxaliplatin/5-FU/FA With or Without Bevacizumab in K-ras Mutant Patients as Neoadjuvant Treatment in Patients With Non- Resectable Colorectal Liver Metastases." @default.
- Q65368182 P17 Q183 @default.
- Q65368182 P1813 "CELIM2" @default.
- Q65368182 P2899 "+18" @default.
- Q65368182 P3098 "NCT01802645" @default.
- Q65368182 P31 Q30612 @default.
- Q65368182 P4844 Q127060 @default.
- Q65368182 P4844 Q27077063 @default.
- Q65368182 P4844 Q412197 @default.
- Q65368182 P4844 Q413299 @default.
- Q65368182 P580 "2013-02-01T00:00:00Z" @default.
- Q65368182 P582 "2017-07-01T00:00:00Z" @default.
- Q65368182 P6099 Q42824440 @default.
- Q65368182 P8363 Q78089383 @default.